Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy

被引：87

作者：

Enzo Ballatori

Fausto Roila

机构：

[1] Medical Statistics Unit, Dept. of Internal Med./Public Health, L'Aquila

[2] Medical Oncology Division, Policlinico Hospital, 06122 Perugia

来源：

Health and Quality of Life Outcomes | / 1卷 / 1期

关键词：

Ondansetron; Metoclopramide; Tropisetron; Emetogenic Chemotherapy; Dolasetron;

D O I：

10.1186/1477-7525-1-46

中图分类号：

学科分类号：

摘要：

It is commonly claimed that the nausea and vomiting accompanying cytotoxic chemotherapy have a negative impact on health-related quality of life. While this may seem self-evident, until a few years ago there was little empirical data demonstrating that the failure to control postchemotherapy emesis affects aspects of quality of life. In spite of their limitations, several observational studies showed that nausea and vomiting associated with chemotherapy induced a decrease in health-related quality of life with respect to patients without nausea and vomiting. This has also been demonstrated after the adjustment for health-related quality of life before chemotherapy that is an important prognostic factor of chemotherapy-induced nausea and vomiting. Furthermore, one study suggests that the optimal time of assessment of quality of life to evaluate the impact of chemotherapy-induced nausea and vomiting is day 4 if a 3-day recall period is used or day 8 when the recall period is 7 days. In double-blind studies the efficacy, tolerability and impact on quality of life of the 5-HT3 receptor antagonists was superior with respect to metoclopramide, alizapride and prochlorperazine. Similar results have been achieved with the combination of ondansetron with dexamethasone, the standard treatment for the prevention of acute emesis induced by moderately emetogenic chemotherapy, with respect to the metoclopramide plus dexamethasone combination. Instead, in another double-blind study, in patients submitted to moderately emetogenic chemotherapy, a 5-HT3 antagonist did not seem to significantly increase complete protection from delayed emesis and the patients' quality of life with respect to dexamethasone alone. In conclusion, the evaluation of quality of life in randomized trials comparing different antiemetic drugs for the prevention of chemotherapy-induced nausea and vomiting can add important information useful for the choice of the optimal antiemetic treatment. © 2003 Ballatori and Roila; licensee BioMed Central Ltd.

引用

页数：11

共 33 条

[1]

Coates A., Abraham S., Kaye S.B., Sowerbutts T., Frewin C., Fox R.M., Tattersall M.H.N., On the receiving end - Patient perception of the side effects of cancer chemotherapy, Eur. J. Cancer Clin. Oncol., 19, pp. 203-208, (1983)

[2]

De Boer-Dennert M., de Wit R., Schmitz P.I.M., Djontono J., van Beurden V., Verweij J., Patient perceptions of the side-effect of chemotherapy: The influence of 5HT<sub>3</sub> antagonists, Br. J. Cancer, 76, pp. 1055-1061, (1997)

[3]

Griffin A.M., Butow P.N., Coates A.S., Childs A.M., Ellis P.M., Dunn S.M., Tattersall M.H.N., On the receiving end: Patient perceptions of the side effects of cancer chemotherapy in 1993, Ann. Oncol., 7, pp. 189-195, (1996)

[4]

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy, N. Engl. J. Med., 342, pp. 1554-1559, (2000)

[5]

Transferability to clinical practice of the results of controlled clinical trials: The case of antiemtic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting, Ann. Oncol., 9, pp. 759-765, (1998)

[6]

Lindley C.M., Hirsch J.D., Nausea and vomiting and cancer patients' quality of life: A discussion of professor Selby's paper, Br. J. Cancer, 66, SUPPL. XIX, (1992)

[7]

Bliss J.M., Robertson B., Selby P.J., The impact of nausea and vomiting upon quality of life measures, Br. J. Cancer, 66, SUPPL. XIX, (1992)

[8]

Lindley C.M., Hirsch J.D., O'Neill C.V., Transau M.C., Gilbert C.S., Osterhaus J.T., Quality of life consequences of chemotherapy-induced emesis, Qual. Life Res., 1, pp. 331-340, (1992)

[9]

Schipper H., Clinch J., McMurray A., Levitt M., Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation, J. Clin. Oncol., 2, pp. 472-483, (1984)

[10]

Berry W.R., House W., Lee J.T., Plagge P.B., Meshad M.W., Grapski R., Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy, Semin. Oncol., 19, 6 SUPPL. 15, pp. 33-37, (1992)

← 1 2 3 4 →